Neurology: Rapid Eye Movement Sleep Behavior Disorder
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objective: To describe the clinical features of rapid eye movement (REM) sleep behavior disorder (RBD), evaluate treatment options, and discuss management of patients with comorbid diseases. Data Sources: A MEDLINE search (1977–April 2007) using the terms REM sleep behavior disorder, narcolepsy, parkinsonian disorders, levodopa, dopamine agonists, clonazepam, benzodiazepines, and melatonin was used to retrieve relevant articles. The reference sections of all articles and texts were scanned for additional literature. Study Selection and Data Extraction: All articles published in English were evaluated. There were no specific criteria for inclusion of articles in this review. Data Synthesis: RBD is characterized by enactment of dream content resulting from the loss of normal skeletal muscle atonia during REM sleep. RBD occurs mainly in geriatric patients and in patients with neurodegenerative diseases, especially parkinsonian diseases. The presence of idiopathic RBD may be a sign of an underlying parkinsonian syndrome. Development of RBD may be one of the first manifestations of Parkinson's disease or other parkinsonian syndromes. An acute form of RBD can be drug-induced or occur on drug withdrawal. The potential for injury to the patient and his or her bed partner is as high as 96%. Controlled trials are unavailable for most agents used in the treatment of RBD, although clonazepam is an effective first-line agent and can provide rapid and complete symptom remission based on evidence from 3 large case series. Patients who cannot tolerate clonazepam or who have a suboptimal response may benefit from melatonin alone or as an adjunct. Both drugs are generally well tolerated when taken at bedtime. Management of patients with RBD becomes complicated due to the high incidence of neurologic comorbidity. Conclusions: Clonazepam is the treatment of choice for patients with RBD. The drug is efficacious and has a low incidence of adverse effects. Melatonin is a viable second-line or adjunctive treatment
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Factors for Hip Fracture in White Women
Cummings, S. R., Nevitt, M. C., Browner, W. S., Stone, K., Fox, K. M., Ensrud, K. E., Cauley, J., Black, D., & Vogt, T. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503233321202 · Cited by 3,595
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671
Brzezinski, A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701163360306 · Cited by 1,549
Schenck, C. H., & Mahowald, M. W. (2002) · SLEEP · doi:10.1093/sleep/25.2.120 · Cited by 770
Cognitive Effects of Long-Term Benzodiazepine Use: A Meta-Analysis
Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418010-00004 · Cited by 552
Schenck, C. H., & Mahowald, M. W. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)89493-4 · Cited by 291
Schenck, C. H., Mahowald, M. W., Kim, S. W., O'Connor, K. A., & Hurwitz, T. D. (1992) · Sleep · doi:10.1093/sleep/15.3.226 · Cited by 261
Sleep Neurobiology for the Clinician
(2004) · Sleep · doi:10.1093/sleep/27.4.811 · Cited by 151
Cited by
Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease
Boeve, B. F., Silber, M. H., Saper, C. B., Ferman, T. J., Dickson, D. W., Parisi, J. E., Benarroch, E. E., Ahlskog, J. E., Smith, G. E., Caselli, R. C., et al. (2007) · Brain · doi:10.1093/brain/awm056 · Cited by 957
Boeve, B. F., Silber, M. H., Ferman, T. J., Lin, S. C., Benarroch, E. E., Schmeichel, A. M., Ahlskog, J. E., Caselli, R. J., Jacobson, S., Sabbagh, M., et al. (2013) · Sleep Medicine · doi:10.1016/j.sleep.2012.10.015 · Cited by 393
Iranzo, A., Santamaria, J., & Tolosa, E. (2009) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2008.11.003 · Cited by 290
Postuma, R. B., Gagnon, J. F., Vendette, M., & Montplaisir, J. Y. (2009) · Brain · doi:10.1093/brain/awp244 · Cited by 260
The Neurobiology of Sleep and Wakefulness
Schwartz, M. D., & Kilduff, T. S. (2015) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.07.002 · Cited by 207
Parasomnias: An Updated Review
Howell, M. J. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0143-8 · Cited by 165
Marques, T. M., Kuiperij, H. B., Bruinsma, I. B., van Rumund, A., Aerts, M. B., Esselink, R. A. J., Bloem, B. R., & Verbeek, M. M. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0253-0 · Cited by 141
Dreams in patients with sleep disorders
Schredl, M. (2009) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2008.06.002 · Cited by 100
The Parasomnias: Epidemiology, Clinical Features, and Diagnostic Approach
Avidan, A. Y., & Kaplish, N. (2010) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2010.02.015 · Cited by 62
Onofrj, M., Thomas, A., & Bonanni, L. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.12.1731 · Cited by 41
Guy de Maupassant and his account of sleep paralysis in his tale, “The Horla”
Miranda, M., & Högl, B. (2013) · Sleep Medicine · doi:10.1016/j.sleep.2013.02.006 · Cited by 11
Metadata
- Authors
- Gugger, J. J., & Wagner, M. L.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2007-11
- Volume
- 41
- Issue
- 11
- Pages
- 1833-1841
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2104443854
- Cited by
- 77
- References
- 8
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.